Eads & Heald Wealth Management Has $985,000 Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Eads & Heald Wealth Management lowered its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,383 shares of the company’s stock after selling 236 shares during the quarter. Eads & Heald Wealth Management’s holdings in IDEXX Laboratories were worth $985,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Perfromance Wealth Partners LLC grew its holdings in shares of IDEXX Laboratories by 2.8% in the 4th quarter. Perfromance Wealth Partners LLC now owns 3,626 shares of the company’s stock valued at $1,499,000 after buying an additional 100 shares during the period. Mogy Joel R Investment Counsel Inc. grew its stake in IDEXX Laboratories by 1.3% in the fourth quarter. Mogy Joel R Investment Counsel Inc. now owns 79,324 shares of the company’s stock valued at $32,796,000 after acquiring an additional 1,010 shares during the period. Atomi Financial Group Inc. increased its holdings in shares of IDEXX Laboratories by 28.4% in the fourth quarter. Atomi Financial Group Inc. now owns 864 shares of the company’s stock worth $357,000 after acquiring an additional 191 shares in the last quarter. Legal Advantage Investments Inc. raised its position in shares of IDEXX Laboratories by 29.7% during the fourth quarter. Legal Advantage Investments Inc. now owns 6,295 shares of the company’s stock worth $2,603,000 after purchasing an additional 1,440 shares during the period. Finally, Seilern Investment Management Ltd bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at about $113,104,000. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on IDXX shares. Leerink Partners began coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a report on Thursday, October 10th. Piper Sandler reaffirmed a “neutral” rating and issued a $435.00 price objective (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Finally, JPMorgan Chase & Co. cut their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $523.86.

IDEXX Laboratories Trading Up 1.9 %

Shares of IDXX stock opened at $427.33 on Wednesday. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39. The company has a market capitalization of $34.99 billion, a PE ratio of 41.21, a price-to-earnings-growth ratio of 3.53 and a beta of 1.36. The firm has a 50 day moving average price of $423.24 and a two-hundred day moving average price of $457.45. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. During the same period last year, the firm posted $2.53 EPS. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, analysts predict that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

Insider Activity at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now owns 905 shares of the company’s stock, valued at $380,498.20. This represents a 27.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.18% of the stock is owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.